Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers

Journal of Alzheimer's Disease

Volumn 50, Issue 1, 2016, Pages 261-270

  Rhodius Meester, Hanneke F M ^a   Koikkalainen, Juha ^b   Mattila, Jussi ^b   Teunissen, Charlotte E ^a   Barkhof, Frederik ^a   Lemstra, Afina W ^a   Scheltens, Philip ^a   L'otj'onen, Jyrki ^b   Van Der Flier, Wiesje M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Alzheimer's disease; clinical decision support system; diagnostic test assessment; mild cognitive impairment; prognosis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PHOSPHORYLATED AT THREONINE 181 PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CLINICAL DECISION SUPPORT SYSTEM; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE ATROPHY; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALGORITHM; COGNITIVE DEFECT; COHORT ANALYSIS; IMAGE PROCESSING; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS;

EID: 84954115153     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150548     Document Type: Article

References (40)

1. World Health Organization (2015) Dementia Fact sheet Number 362. http://www.who.int/mediacentre/factsheets/fs362/ en/
2. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
3. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM (2013) Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. Lancet Neurol 12, 957-965.
4. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
5. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
6. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
7. Boccardi M, Ganzola R, Bocchetta M, Pievani M, Redolfi A, Bartzokis G, Camicioli R, Csernansky JG, De Leon MJ, deToledo-Morrell L, Killiany RJ, Lehericy S, Pantel J, Pruessner JC, Soininen H,Watson C, Duchesne S, JackCRJr, Frisoni GB(2011) Survey of protocols for the manual segmentation of the hippocampus: Preparatory steps towards a joint EADCADNI harmonized protocol. J Alzheimers Dis 26(Suppl 3) , 61-75.
8. Sperling R, Johnson K (2013) Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria. Continuum (Minneap Minn) 19, 325-338.
9. Blennow K, Dubois B, Fagan AM, Lewczuk P, De Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69.
10. Liu Y, Mattila J, Ruiz MA, Paajanen T, Koikkalainen J, van Gils GM, Herukka SK, Waldemar G, Lotjonen J, Soininen H (2013) Predicting AD conversion: Comparison between prodromal AD guidelines and computer assisted PredictAD tool. PLoS One 8, e55246.
11. Antila K, Lotjonen J, Thurfjell L, Laine J, Massimini M, Rueckert D, Zubarev RA, Oresic M, van Gils GM, Mattila J, Hviid SA,Waldemar G, Soininen H (2013) The PredictAD project: Development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus 3, 20120072.
12. Mattila J, Koikkalainen J, Virkki A, van Gils GM, Lotjonen J (2012) Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng 59, 234-240.
13. Simonsen AH, Mattila J, Hejl AM, Frederiksen KS, Herukka SK, Hallikainen M, van Gils GM, Lotjonen J, Soininen H, Waldemar G (2012) Application of the PredictAD software tool to predict progression in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 34, 344-350.
14. Mattila J, Soininen H, Koikkalainen J, Rueckert D, Wolz R, Waldemar G, Lotjonen J (2012) Optimizing the diagnosis of early Alzheimer's disease in mild cognitive impairment subjects. J Alzheimers Dis 32, 969-979.
15. Soininen H, Mattila J, Koikkalainen J, van Gils GM, Hviid SA,Waldemar G, Rueckert D, Thurfjell L, Lotjonen J (2012) Software tool for improved prediction of Alzheimer's disease. Neurodegener Dis 10, 149-152.
16. Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils GM, Waldemar G, Soininen H, Lotjonen J (2011) A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis 27, 163-176.
17. Hall A, Mattila J, Koikkalainen J, Lotjonen J,Wolz R, Scheltens P, Frisoni G, Tsolaki M, Nobili F, Freund-LeviY, Minthon L, Frolich L, Hampel H, Visser PJ, Soininen H (2015) Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index. Curr Alzheimer Res 12, 69-79.
18. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, van EE, Scheltens P (2014) Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis 41, 313-327.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
20. Verhage F (2015) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenzeventig jaar [Intelligence and Age: Study with Dutch people aged 12 to 77], Van Gorcum, Assen.
21. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
22. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA(1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol 242, 557-560.
23. Pasquier F, Leys D,Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36, 268-272.
24. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149, 351-356.
25. Munoz-Ruiz MA, Hartikainen P, Hall A, Mattila J, Koikkalainen J, Herukka SK, Julkunen V, Vanninen R, Liu Y, Lotjonen J, Soininen H (2013) Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis 35, 727-739.
26. van de Pol LA, Scheltens P (2014) Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on 'influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs'. J Intern Med 275, 331-333.
27. Mulder C,VerweyNA, van der FlierWM,Bouwman FH,Kok A, van Elk EJ, Scheltens P, BlankensteinMA(2010) Amyloidbeta( 1-42) , total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
28. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schroder J, Aarsland D, Blankenstein MA, Scheltens P, van der FlierWM(2014) The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? Alzheimers Dement 10, 713-723.e2.
29. Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Ruther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Muscio C, Herukka SK, Salmon E, Bastin C, Wallin A, Nordlund A, de MA, Silva D, Santana I, Lemos R, Engelborghs S, Van der Mussele S, Freund-Levi Y, Wallin AK, Hampel H, van der Flier W, Scheltens P, Visser PJ (2015) Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138(Pt 5) 1327-1338.
30. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3, 32-35.
31. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ (2013) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 9, e111-e194.
32. Hall A, Munoz-Ruiz M, Mattila J, Koikkalainen J, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Lovestone S, Visser PJ, Lotjonen J, Soininen H (2015) Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 44, 79-92.
33. Munoz-Ruiz MA, Hall A, Mattila J, Koikkalainen J, Herukka SK, Vanninen R, Liu Y, Lotjonen J, Soininen H (2014) Comparing predictors of conversion to Alzheimer's disease using the disease state index. Neurodegener Dis 13, 200-202.
34. Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: Six-year follow-up study. PLoS One 7, e38639.
35. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238.
36. Gainotti G, Quaranta D, Vita MG, Marra C (2014) Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 38, 481-495.
37. Vos S, van R, Burns I, Knol L, Scheltens D, Soininen P, Wahlund H, Hampel LO, Tsolaki H, Minthon M, Handels L, L'Italien R, van der Flier G, AaltenW, Teunissen P, Barkhof C, BlennowF,Wolz K, Rueckert R,VerheyD,Visser F, PJ (2012) Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 33, 2272-2281.
38. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
39. Prestia A, Caroli A,Wade SK, van der Flier WM, Ossenkoppele R, Van BB, Barkhof F, Teunissen CE, Wall A, Carter SF, Scholl M, Choo IH, Nordberg A, Scheltens P, Frisoni GB (2015) Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement 11, 1191-1201.
40. Guo LH, Alexopoulos P, Eisele T, Wagenpfeil S, Kurz A, Perneczky R (2013) The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: Predicting the outcome. Eur Arch Psychiatry Clin Neurosci 263, 325-333.